{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:27:12Z","timestamp":1792902432237,"version":"4.5.0"},"reference-count":180,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009859","name":"Memorial Sloan-Kettering Cancer Center Geoffrey Beene Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007623","name":"Emory University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014561","name":"Juno Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA190174 05"],"award-info":[{"award-number":["P01 CA190174 05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA192937 05"],"award-info":[{"award-number":["P50 CA192937 05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 CA241894 01A1"],"award-info":[{"award-number":["R35 CA241894 01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA023766 40"],"award-info":[{"award-number":["P01 CA023766 40"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 CA184746 06"],"award-info":[{"award-number":["K12 CA184746 06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA256801-01"],"award-info":[{"award-number":["U01 CA256801-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA009512-29A1"],"award-info":[{"award-number":["T32 CA009512-29A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ymthe.2022.02.012","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T20:37:27Z","timestamp":1644525447000},"page":"1381-1395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Multipurposing CARs: Same engine, different vehicles"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1792-4528","authenticated-orcid":false,"given":"A.K.M. Nawshad","family":"Hossian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-2433","authenticated-orcid":false,"given":"Christopher S.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3065","authenticated-orcid":false,"given":"Sarwish","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.02.012_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/d41573-019-00090-z","article-title":"The global pipeline of cell therapies for cancer","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.02.012_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.02.012_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd.2018.167","article-title":"Trends in the global immuno-oncology landscape","volume":"17","author":"Tang","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.02.012_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.02.012_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy - moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.012_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41587-021-00929-0","article-title":"Therapy to target BCMA gets FDA nod","volume":"39","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","author":"Albinger","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor T\u00a0cell therapy: challenges to bench-to-bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PPO.0000000000000510","article-title":"Using adoptive cellular therapy for localized protein secretion","volume":"27","author":"Evans","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.ymthe.2022.02.012_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2022.02.012_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ni.1841","article-title":"Raising the NKT cell family","volume":"11","author":"Godfrey","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib17","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/eji.200425958","article-title":"Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples","volume":"35","author":"Berzins","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1172\/JCI0215832","article-title":"Testing the NKT cell hypothesis of human IDDM pathogenesis","volume":"110","author":"Lee","year":"2002","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2022.02.012_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","article-title":"Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T\u00a0cell-clonotypic monoclonal antibody, 6B11","volume":"122","author":"Montoya","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2022.02.012_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri3328","article-title":"Recognition of CD1d-restricted antigens by natural killer T\u00a0cells","volume":"12","author":"Rossjohn","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib22","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.171.10.5140","article-title":"NKT cells enhance CD4+ and CD8+ T\u00a0cell responses to soluble antigen in\u00a0vivo through direct interaction with dendritic cells","volume":"171","author":"Hermans","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/cimm.1999.1602","article-title":"alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells","volume":"199","author":"Kitamura","year":"2000","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ymthe.2022.02.012_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T\u00a0cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in\u00a0vivo and thereby acts as an adjuvant for combined CD4 and CD8 T\u00a0cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib25","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3389\/fimmu.2018.01360","article-title":"Activation and regulation of B cell responses by invariant natural killer T\u00a0cells","volume":"9","author":"Doherty","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T\u00a0cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T\u00a0cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.02.012_bib28","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in\u00a0vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib29","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib30","unstructured":"Allogeneic NKT for Patients with Relapsed or Refractory B-Cell Malignancies (ANCHOR) https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03774654."},{"key":"10.1016\/j.ymthe.2022.02.012_bib31","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in\u00a0vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2022.02.012_bib32","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation\u201d","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.0813192106","article-title":"Cytokine-induced memory-like natural killer cells","volume":"106","author":"Cooper","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.02.012_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib35","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T\u00a0cells","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib36","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In\u00a0vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib37","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V97.10.2923","article-title":"Expansion of cytolytic CD8(+) natural killer T\u00a0cells with limited capacity for graft-versus-host disease induction due to interferon gamma production","volume":"97","author":"Baker","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib38","unstructured":"Transposon-manipulated allogeneic CARCIK-CD19 cells in pediatric and adult patients with r\/r ALL post HSCT. https:\/\/ClinicalTrials.gov\/show\/NCT03389035."},{"key":"10.1016\/j.ymthe.2022.02.012_bib39","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T\u00a0cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2022.02.012_bib40","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.ymthe.2020.05.021","article-title":"Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system","volume":"28","author":"Rotiroti","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib41","doi-asserted-by":"crossref","first-page":"581468","DOI":"10.3389\/fimmu.2020.581468","article-title":"ERBB2-CAR-Engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma","volume":"11","author":"Merker","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib42","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/1078-0432.CCR-20-0357","article-title":"CSPG4-Specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft-tissue sarcoma histotypes","volume":"26","author":"Leuci","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib43","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.131202998","article-title":"How the immune system works to protect the host from infection: a personal view","volume":"98","author":"Janeway","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.02.012_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T\u00a0cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib45","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","article-title":"Broad tumor-associated expression and recognition by tumor-derived gamma delta T\u00a0cells of MICA and MICB","volume":"96","author":"Groh","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.02.012_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2013.00069","article-title":"Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells","volume":"4","author":"Hudspeth","year":"2013","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib47","doi-asserted-by":"crossref","first-page":"e22892","DOI":"10.4161\/onci.22892","article-title":"Tumor cell recognition by gammadelta T lymphocytes: T-cell receptor vs. NK-cell receptors","volume":"2","author":"Correia","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2022.02.012_bib48","doi-asserted-by":"crossref","first-page":"E5980","DOI":"10.1073\/pnas.1720564115","article-title":"Distinct human circulating NKp30(+)FcepsilonRIgamma(+)CD8(+) T\u00a0cell population exhibiting high natural killer-like antitumor potential","volume":"115","author":"Correia","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.02.012_bib49","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.4049\/jimmunol.175.4.2144","article-title":"Activation of V gamma 9V delta 2 T\u00a0cells by NKG2D","volume":"175","author":"Rincon-Orozco","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib50","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.4049\/jimmunol.174.10.6045","article-title":"Gamma delta T\u00a0cells respond directly to pathogen-associated molecular patterns","volume":"174","author":"Hedges","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of gammadelta T\u00a0cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib52","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib53","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib54","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2022.02.012_bib55","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T\u00a0cells from iPSCs derived from mature CD8(+) T\u00a0cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2022.02.012_bib57","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","article-title":"Enhancing T\u00a0cell receptor stability in rejuvenated iPSC-derived T\u00a0cells improves their use in cancer immunotherapy","volume":"23","author":"Minagawa","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2022.02.012_bib58","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-16-1149","article-title":"Regeneration of CD8alphabeta T\u00a0cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity","volume":"76","author":"Maeda","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib59","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.02.012_bib61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.12.006","article-title":"High frequency production of T\u00a0cell-derived iPSC clones capable of generating potent cytotoxic T\u00a0cells","volume":"16","author":"Nagano","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.02.012_bib62","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2012.11.003","article-title":"T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures","volume":"2","author":"Kennedy","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.ymthe.2022.02.012_bib63","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T\u00a0cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.02.012_bib64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T-reg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib65","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T\u00a0cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2022.02.012_bib66","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T\u00a0cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2022.02.012_bib67","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T\u00a0cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2022.02.012_bib68","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/bloodadvances.2019000411","article-title":"Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice","volume":"3","author":"Bezie","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2022.02.012_bib69","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T\u00a0cells","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.02.012_bib70","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/ajt.15787","article-title":"Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients","volume":"20","author":"Sicard","year":"2020","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2022.02.012_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcyt.2020.10.002","article-title":"HLA-A\u221702:01-directed chimeric antigen receptor\/forkhead box P3-engineered CD4+T cells adopt a regulatory phenotype and suppress established graft-versus-host disease","volume":"23","author":"Martin","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2022.02.012_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202048934","article-title":"Chimeric antigen receptor-modified human regulatory T\u00a0cells that constitutively express IL-10 maintain their phenotype and are potently suppressive","author":"Mohseni","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.02.012_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T\u00a0cells suppress B cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"Jci Insight"},{"key":"10.1016\/j.ymthe.2022.02.012_bib75","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T\u00a0cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2022.02.012_bib76","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T\u00a0cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2022.02.012_bib77","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T\u00a0cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib79","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T\u00a0cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104216","article-title":"CD4(+) T\u00a0cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice","volume":"358","author":"Fu","year":"2020","journal-title":"Cell Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib81","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T\u00a0cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00693","article-title":"Suppression of FVIII-specific memory B cells by chimeric BAR receptor-engineered natural regulatory T\u00a0cells","volume":"11","author":"Pohl","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib83","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric antigen receptor-redirected regulatory T\u00a0cells suppress experimental allergic airway inflammation, a model of asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib84","doi-asserted-by":"crossref","first-page":"176.17","DOI":"10.4049\/jimmunol.200.Supp.176.17","article-title":"Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis","volume":"200","author":"Raffin","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by Tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib86","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2022.02.012_bib87","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T\u00a0cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ymthe.2022.02.012_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104224","article-title":"Towards antigen-specific Tregs for type 1 diabetes: construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor","volume":"358","author":"Radichev","year":"2020","journal-title":"Cell Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib89","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/gt.2009.75","article-title":"Redirecting human CD4+CD25+ regulatory T\u00a0cells from the peripheral blood with pre-defined target specificity","volume":"16","author":"Hombach","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib90","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In\u00a0vivo inhibition of human CD19-targeted effector T\u00a0cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib91","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omtm.2020.11.008","article-title":"Genetic engineering of human and mouse CD4(+) and CD8(+) Tregs using lentiviral vectors encoding chimeric antigen receptors","volume":"20","author":"Vimond","year":"2021","journal-title":"Mol. Ther-meth Clin. D"},{"key":"10.1016\/j.ymthe.2022.02.012_bib92","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.tibtech.2019.12.009","article-title":"Toward an optimized process for clinical manufacturing of CAR-treg cell therapy","volume":"38","author":"Fritsche","year":"2020","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T\u00a0cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci. Translational Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib94","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T\u00a0cell function","volume":"5","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.02.012_bib95","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","author":"Rafiq","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib96","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaut.2018.02.006","article-title":"Engrafting human regulatory T\u00a0cells with a flexible modular chimeric antigen receptor technology","volume":"90","author":"Koristka","year":"2018","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ymthe.2022.02.012_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells--a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib98","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-immunol-041015-055549","article-title":"The innate lymphoid cell precursor","volume":"34","author":"Ishizuka","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib99","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ijc.2910160205","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells","volume":"16","author":"Herberman","year":"1975","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2022.02.012_bib100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41388-020-01561-z","article-title":"The role of natural killer cell in gastrointestinal cancer: killer or helper","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2022.02.012_bib101","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8(+) T\u00a0cells","volume":"11","author":"Sun","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib102","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib103","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.02.012_bib104","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2002-04-1164","article-title":"Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages","volume":"101","author":"Delneste","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib106","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/aps.2017.125","article-title":"Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy","volume":"39","author":"Hu","year":"2018","journal-title":"Acta Pharmacol. Sin"},{"key":"10.1016\/j.ymthe.2022.02.012_bib107","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in\u00a0vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib108","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T\u00a0cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib109","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2022.02.012_bib110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib111","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2022.02.012_bib112","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2022.02.012_bib113","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib114","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2022.02.012_bib115","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2022.02.012_bib116","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib117","article-title":"Natural killer cells and current applications of chimeric antigen receptor-modified NK-92 cells in tumor immunotherapy","volume":"20","author":"Zhang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.02.012_bib118","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Schonfeld","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib119","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcyt.2014.09.007","article-title":"Challenges of cancer therapy with natural killer cells","volume":"17","author":"Klingemann","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2022.02.012_bib120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2022.02.012_bib121","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2022.02.012_bib122","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib123","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib124","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.stemcr.2014.01.014","article-title":"Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells","volume":"2","author":"Valamehr","year":"2014","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2022.02.012_bib125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2022.02.012_bib126","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/1535-7163.MCT-19-0893","article-title":"Characterization of 7A5: a human CD137 (4-1BB) receptor binding monoclonal antibody with differential agonist properties that promotes antitumor immunity","volume":"19","author":"Kotanides","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib127","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib128","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ymthe.2022.02.012_bib130","doi-asserted-by":"crossref","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2022.02.012_bib131","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in\u00a0vitro and in\u00a0vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2022.02.012_bib132","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.02.012_bib133","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ni929","article-title":"NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway","volume":"4","author":"Billadeau","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib134","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/35642","article-title":"Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells","volume":"391","author":"Lanier","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.02.012_bib135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0198-8859(99)00170-6","article-title":"2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism","volume":"61","author":"Nakajima","year":"2000","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T\u00a0cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib137","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"Topfer","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib138","doi-asserted-by":"crossref","first-page":"652223","DOI":"10.3389\/fimmu.2021.652223","article-title":"CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in\u00a0vitro","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib139","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib141","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib142","first-page":"393","article-title":"The development of fibroblast colonies in monolayer cultures of Guinea-pig bone marrow and spleen cells","volume":"3","author":"Friedenstein","year":"1970","journal-title":"Cell Tissue Kinet"},{"key":"10.1016\/j.ymthe.2022.02.012_bib143","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1537-2995.1971.tb04426.x","article-title":"Fibroblast colony formation from monolayer cultures of blood cells","volume":"11","author":"Luria","year":"1971","journal-title":"Transfusion"},{"key":"10.1016\/j.ymthe.2022.02.012_bib144","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.it.2011.11.004","article-title":"How mesenchymal stem cells interact with tissue immune responses","volume":"33","author":"Shi","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib146","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.stem.2014.06.008","article-title":"Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow","volume":"15","author":"Zhou","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2022.02.012_bib147","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","article-title":"Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth","volume":"19","author":"Quante","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2022.02.012_bib148","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.stem.2012.08.013","article-title":"CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha","volume":"11","author":"Ren","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2022.02.012_bib149","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications","volume":"15","author":"Wang","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.leu.2404489","article-title":"Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in\u00a0vivo tumor growth","volume":"21","author":"Ramasamy","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2022.02.012_bib151","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1182\/blood-2003-04-1193","article-title":"Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals","volume":"102","author":"Djouad","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib152","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2006-05-020800","article-title":"Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis","volume":"109","author":"Ame-Thomas","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib153","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","article-title":"Mesenchymal stem cells within tumour stroma promote breast cancer metastasis","volume":"449","author":"Karnoub","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.02.012_bib154","doi-asserted-by":"crossref","first-page":"e9750","DOI":"10.1371\/journal.pone.0009750","article-title":"Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma","volume":"5","author":"Balyasnikova","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.02.012_bib155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-3-12","article-title":"Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor","volume":"3","author":"Komarova","year":"2010","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib156","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41417-018-0062-x","article-title":"Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors","volume":"27","author":"Golinelli","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2022.02.012_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040873","article-title":"IL7-IL12 engineered mesenchymal stem cells (MSCs) improve A CAR T\u00a0cell attack against colorectal cancer cells","volume":"9","author":"Hombach","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2022.02.012_bib158","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.02.012_bib159","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib160","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors","volume":"121","author":"Kerkar","year":"2011","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2022.02.012_bib161","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ymthe.2022.02.012_bib162","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1471-4906(01)02028-2","article-title":"Interleukin-7: master regulator of peripheral T-cell homeostasis?","volume":"22","author":"Fry","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib163","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.it.2005.01.004","article-title":"IL-7: maintaining T-cell memory and achieving homeostasis","volume":"26","author":"Bradley","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib164","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cytogfr.2005.05.004","article-title":"Cell biology of IL-7, a key lymphotrophin","volume":"16","author":"Jiang","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2022.02.012_bib165","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1038\/bcj.2015.73","article-title":"Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T\u00a0cells towards acute myeloid leukemia blasts","volume":"5","author":"Aliperta","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2022.02.012_bib166","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00281-013-0367-7","article-title":"Tumor-associated macrophages: functional diversity, clinical significance, and open questions","volume":"35","author":"Biswas","year":"2013","journal-title":"Semin. Immunopathol"},{"key":"10.1016\/j.ymthe.2022.02.012_bib167","doi-asserted-by":"crossref","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.02.012_bib168","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1471-2407-12-306","article-title":"The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients","volume":"12","author":"Medrek","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2022.02.012_bib169","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","article-title":"Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues","volume":"104","author":"Murdoch","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.02.012_bib170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2022.02.012_bib171","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib172","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-2563","article-title":"Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies","volume":"78","author":"Velazquez","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.02.012_bib173","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib174","doi-asserted-by":"crossref","first-page":"669103","DOI":"10.3389\/fimmu.2021.669103","article-title":"CAR macrophages for SARS-CoV-2 immunotherapy","volume":"12","author":"Fu","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib175","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.02.012_bib176","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T\u00a0cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.02.012_bib177","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T\u00a0cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2022.02.012_bib178","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T\u00a0cells with distinct costimulatory domains mitigate HIV pathogenesis in\u00a0vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.02.012_bib179","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T\u00a0cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.02.012_bib180","doi-asserted-by":"crossref","first-page":"28950","DOI":"10.1073\/pnas.2012495117","article-title":"A biomimetic five-module chimeric antigen receptor ((5M)CAR) designed to target and eliminate antigen-specific T\u00a0cells","volume":"117","author":"Kobayashi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:05:49Z","timestamp":1778616349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1525001622000958"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multipurposing CARs: Same engine, different vehicles","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}